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Abstract
The lack of appropriate tumor models of primary tumors and corresponding metastases that can reliably predict for
response to anticancer agents remains a major deficiency in the clinical practice of cancer therapy. It was the aim of our
study to establish patient-derived tumor tissue (PDTT) xenograft models of colon carcinoma with lymphatic and hepatic
metastases useful for testing of novel molecularly targeted agents. PDTT of primary colon carcinoma, lymphatic and hepatic
metastases were used to create xenograft models. Hematoxylin and eosin staining, immunohistochemical staining,
genome-wide gene expression analysis, pyrosequencing, qRT-PCR, and western blotting were used to determine the
biological stability of the xenografts during serial transplantation compared with the original tumor tissues. Early passages
of the PDTT xenograft models of primary colon carcinoma, lymphatic and hepatic metastases revealed a high degree of
similarity with the original clinical tumor samples with regard to histology, immunohistochemistry, genes expression, and
mutation status as well as mRNA expression. After we have ascertained that these xenografts models retained similar
histopathological features and molecular signatures as the original tumors, drug sensitivities of the xenografts to a novel
VEGF targeted agent, FP3 was evaluated. In this study, PDTT xenograft models of colon carcinoma with lymphatic and
hepatic metastasis have been successfully established. They provide appropriate models for testing of novel molecularly
targeted agents.
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Introduction
Animal models have been used in front-line preclinical studies
for predicting efficacy and possible toxicities of anticancer drugs in
cancer patients [1]. Advancing a laboratory candidate drug from
preclinical testing into testing in phase II clinical trials is based on
the assumption that cancer models used in the laboratory are
clinically predictive [2]. One of the most serious obstacles
confronting investigators involved in the development and
assessment of new anticancer drugs is the failure of rodent tumor
models to predict reliably as to whether a given drug will have
prospective anticancer activity with acceptable toxicity when
applied to humans. Current tumor models used for drug
evaluation generally consist of implantation into immunodeficient
mice of xenografts generated from well-established human cancer
cell lines that have already adapted to in vitro growth. These
models have been used extensively for decades for rapid screening
of the anticancer drug efficacy [3,4]. Such models have proven
useful for identifying cellular and molecular mechanisms under-
lying metastasis and for developing new therapeutics. However,
limited effectiveness exists, which severely restrains the predictive
power of such models assessing the responses of patients’ tumors to
anticancer drugs in the clinic. The highly anaplastic cancer cells
cultivated in vitro represent the extreme derivates from highly
advanced cancers and are not associated with original tumor
stroma, which now has been recognized as a crucial factor in the
pathogenesis of cancer metastasis. In recent years, various groups
have initiated the development of more relevant models based on
xenografting of primary human tumor tissue in immunodeficient
mice. Such patient-derived tumor tissue (PDTT) xenograft models
are mainly constructed by introducing advanced tumor cells into
the subcutaneous graft site. These xenografts models retain similar
morphology, architecture and molecular signatures as the original
cancers and thus should be used for rapid screening of potential
therapeutics.
In recent years, many studies have focused on the heterogeneity
found in primary tumors and corresponding metastases with the
consideration that evaluation of metastatic rather than primary
sites could be of clinical relevance [5]. Numerous reports have
evaluated the heterogeneity in primary tumors and corresponding
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[6,7,8,9,10,11,12,13], colorectal cancer [14,15,16,17] and non-
small cell lung cancer (NSCLC) [18,19]. The main purpose of
investigating the heterogeneity found in primary tumors and
corresponding metastases is to evaluate the effect of such
heterogeneity on the efficacy of anticancer therapy and cancer
patients’ prognosis. The primary tumor and its corresponding
metastases are different at the molecular marker expression or
gene status levels and that these differences may affect the clinical
outcome of anticancer therapy [20]. Monaco et al. suggested that
the EGFR and KRAS status of primary lung carcinomas might not
predict the status in the corresponding metastases. Their
observation may have important implications for molecular testing
for EGFR-targeted therapies [21]. A retrospective study investi-
gated the role of PTEN loss, Akt phosphorylation and KRAS
mutations in primary colorectal tumors and their corresponding
metastases on the activity of cetuximab plus irinotecan [22]. This
study gave us direct evidence to reveal that the genetic
heterogeneity in primary colorectal tumors and their correspond-
ing metastases have different responses to EGFR-targeted therapy.
On these considerations mentioned above, to establish the PDTT
xenograft models of primary tumor and corresponding metastases
for assessment of the response of both the primary tumor and the
metastases to some novel drugs is extremely useful.
FP3 (also named as KH902 or KH903) is an engineered protein
which contains the extracellular domain 2 of VEGF receptor 1
(Flt-1) and extracellular domain 3 and 4 of VEGF receptor 2 (Flk-
1, KDR) fused to the Fc portion of human immunoglobulin G1
[23,24]. Previous studies indicated that FP3 had promise as a local
antiangiogenic treatment of human CNV (choroidal neovascular-
ization) -related AMD (age-related macular degeneration)
[23,25,26,27]. In subsequent studies, it was demonstrated that
FP3 has an inhibitory efficacy in VEGF-mediated proliferation
and migration of human umbilical vein endothelial cells, and in
VEGF-mediated vessel sprouting of rat aortic ring in vitro [24]. It
was also demonstrated that FP3 has an antitumor effect in a
NSCLC cell line (A549) xenograft model [24] and a PDTT
xenograft model of gastric carcinoma [28] in nude mice.
It was the aim of our study to establish PDTT xenograft models
of colon carcinoma with lymphatic and hepatic metastasis useful
for testing of a novel molecularly targeted agent, FP3.
Materials and Methods
Reagents and drugs
Anti-Akt, anti-ERK, anti-MAPK and anti-mTOR antibodies,
and phosphorylation-specific antibodies against Akt (Ser
308 and
Ser
473), ERK (Thr
202/Tyr
204), MAPK (Thr
180/Tyr
182) and
mTOR (Ser
2448) were purchased from Cell Signaling Technology
Inc. (Cell Signaling, Beverly, MA). The antibodies against cleaved-
caspase-3, VEGFR-2, and PCNA were purchased from Cell
Signaling Technology Inc. (Cell Signaling, Beverly, MA). The
antibodies against CK-20 (human-specific) and CDX-2 (human-
specific) were purchased from DAKO (Carpinteria, CA). The
antibodies against VEGF (human-specific) and EGFR were
purchased from Epitomics Inc. (Burlingame, CA). The antibody
against platelet endothelial cell adhesion molecule-1 (PECAM-1,
CD31) (rat monoclonal, clone MEC 13.3) was purchased from BD
Pharmingen (San Diego, CA). The antibody against a-smooth
muscle actin (a-SMA, rabbit polyclonal) was purchased from
Abcam (Cambridge, UK). Fluorescent (Cy3- or FITC-conjuncted)
secondary antibodies (goat anti-rat or anti-rabbit) were purchased
from Jackson ImmunoResearch (West Grove, PA). The antibody
against GAPDH was purchased from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA). Horseradish peroxidase-conjugated
secondary antibodies were purchased from Santa Cruz Biotech-
nology, Inc. (Santa Cruz, CA). Chemiluminescent detection
system was purchased from Amersham Pharmacia Biotech
(Arlington Heights, IL). RPMI 1640 medium, fetal bovine serum
(FBS), penicillin, and streptomycin were purchased from Gibco
(Grand Island, NY, USA). Isofluorane, diethyl ether, ketamine,
and xylazine were purchased from Sigma (St. Louis, MO, USA).
Bevacizumab (Avastin) was purchased from Roche, Inc. (Roche,
USA). FP3 was kindly provided as a gift from Kanghong,
Biotechnology Inc. (Konghong, Chengdu, China).
Patient and tissue samples
Tumor specimens were obtained at initial surgery from a 40-
year-old female colon carcinoma patient with lymphatic and
hepatic metastases. Prior written informed consent was obtained
from the patient and the study received ethics board approval at
First Affiliated Hospital, College of Medicine, Zhejiang University.
The patient had not received chemotherapy or radiation therapy
before surgery. The histological type was determined according to
WHO criteria. The tumor was diagnosed as mucinous adenocar-
cinoma (T3N2M1). The tumor samples of colon carcinoma with
lymphatic and hepatic metastases were put into medium
immediately after surgical resection under sterile conditions and
transported without delay to the animal facility.
Establishment of xenografts
Four- to six-week-old female BALB/c nude mice purchased
from Slaccas (Slaccas Laboratory Animal, Shanghai, China) were
housed in a barrier facility and acclimated to 12-h light-dark cycles
for at least three days before use. The use of experimental animals
adhered to the ‘‘Principles of Laboratory Animal Care’’ (NIH
publication #85-23, revised in 1985). All experiments were
approved by the Institutional Animal Care and Use Committee
of Zhejiang University (approval ID: SYXK(ZHE)2005-0072).
The method to establish the PDTT xenograft models of human
colon carcinoma with lymphatic and hepatic metastases were
followed as described previously [5,28,29,30]. Briefly, tumors were
placed in RPMI 1640 medium supplemented with 20% FBS and
0.05% penicillin/streptomycin solution in an ice bath in the
surgical site. Tumors were then transferred to a sterile Petri dish
containing RPMI 1640 medium with supplements mentioned
above. Thin slices of tumor were diced into 26263m m
3 pieces
and washed thrice with RPMI 1640 with supplements mentioned
above. Under anesthesia with isofluorane, tumors were implanted
into 4- to 6-week-old female athymic nude mice by a small incision
and subcutaneous pocket made in one side of the lower back in
which one tumor piece is deposited in the pocket. While the pocket
was still open, one drop of 1006penicillin/streptomycin solution
was placed into the opening. Half of the rest of the tumors was
cryopreserved in liquid nitrogen and the other half was
immediately snap-frozen and stored at 280uC and processed for
biological studies, such as genetic, genomic, mRNA expression
and protein expression analyses. For each tumor, twenty mice
were used. Growth of established tumor xenografts was monitored
at least twice weekly by vernier caliper measurement of the length
(a) and width (b) of tumor. Tumor volumes was calculated as
(a6b
2)/2. For the first week following implantation, a small bump
would be visible where the tumor was inserted. At 14 to 22 weeks
following implantation, a tumor began to appear at the site of
implantation with 1000 to 1500 mm
3 in volume. At a size of about
1500 mm
3, tumors were removed for serial transplantation.
Tumor-bearing animals were anesthetized with diethyl ether and
sacrificed by cervical dislocation. Animals were placed immedi-
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placed in 75% ethanol for 2 minutes, and transferred to a laminar
flow hood for dissection. Tumors were minced under sterile
conditions and implanted in successive nude mice as described
above. Tumors were passaged no more than 10 times. Following
transplantation, tumors were allowed to grow to 200 to 500 mm
3
before initiation of treatment for drug evaluation. Numerous
samples from early passages were stored in the tissue bank and
cryopreserved in liquid nitrogen, and used for further experiments.
Treatment protocol
Xenografts from this second mouse-to-mouse passage (the third
generation, G3) were allowed to grow to a size of 200 mm
3,a t
which time mice were randomized in the following three groups of
treatment, with 10 mice in each group: (a) control (100 ml saline);
(b) FP3, 15 mg/kg, i.v., twice per week; (c) Avastin (bevacizumab),
10 mg/kg, i.v., twice per week. Mice were treated during 21 days,
monitored twice per week for signs of toxicity, and were weighed
once a week. Tumor size was evaluated twice a week by caliper
measurements using the following formula: tumor volume =
(length6width
2)/2. Relative tumor growth inhibition (TGI) was
calculated by relative tumor growth of treated mice divided by
relative tumor growth of control mice (T/C). Experiments were
terminated on day 30.
Histology and immunohistochemistry
Selected tumor specimen were fixed in 10% neutral-buffered
formalin and embedded in paraffin. Five-micrometer sections were
cut, dewaxed, and then rehydrated and stained with hematoxylin
and eosin (H&E) as described previously [31,32].
For immunohistochemical staining, five micromolar sections
were cut, dewaxed, rehydrated, and subjected to antigen retrieval.
After blocking endogenous peroxidase activity, the sections were
incubated with the primary antibodies against CK-20 (1:100),
CDX-2 (1:100), EGFR (1:100), VEGF (1:100) and PCNA (1:100)
(overnight at 4uC). Immunohistochemistry was performed using
the streptavidin-biotin peroxidase complex method (Lab Vision,
Fremont, CA). The slides were examined and pictures were taken
using an Olympus BX60 (Olympus, Japan). Sections known to
stain positively were incubated in each batch and negative controls
were also prepared by replacing the primary antibody with
preimmune sera.
Fluorescent immunohistochemistry
Selected mice with similar tumor size were anesthetized with
ketamine (87 mg/kg) plus xylazine (13 mg/kg) injected intra-
muscularly. The chest was opened rapidly, and the vasculature
was perfused for 3 minutes at a pressure of 120 mmHg with
fixative [4% paraformaldehyde in 0.1 mol/L phosphate-buffered
saline (PBS), pH 7.4] from an 18-gauge cannula inserted into the
aorta via an incision in the left ventricle. Blood and fixative
exited through an opening in the right atrium. After the
perfusion, the implanted tumor was removed and placed into
fixative for 2 hours at 4uC. Specimens were then rinsed several
times with PBS, infiltrated overnight with 30% sucrose,
embedded in OCT medium and frozen for cryostat sectioning
[33]. Cryostat sections 8 to 10 mm in thickness were brought to
room temperature, air dried overnight, then fixed in acetone for
10 min. Slides were allowed to air dry for 30 min and were
washed three times for 5 min each in PBS. Samples were then
incubated in 5% BSA in PBS for 30 min at room temperature to
block nonspecific antibody binding. Next, the sections were
incubated with two primary antibodies (CD31, 1:100; and a-
SMA, 1:200) or VEGFR-2 (1:150) overnight at room temper-
ature in humidified chambers diluted in PBS. After several rinses
with PBS, specimens were incubated for 1 hour at room
temperature with fluorescent (Cy3- or FITC-conjuncted) sec-
ondary antibodies (goat anti-rat or goat anti-rabbit) diluted
(1:200) in PBS. Specimens were rinsed again with PBS, and
mounted in Vectashield (Vector Laboratories, Burlingame, CA)
[34,35]. Tissue sections were examined and digitally photo-
graphed using a Zeiss Axiophot fluorescence microscope (Carl
Zeiss, Thornwood, NY) equipped with single, dual, and triple
fluorescence filters and a low-light, externally cooled, three-chip
charge-coupled device (CCD) camera (4806640 pixel RGB-
color images, CoolCam; SciMeasure Analytical Systems,
Atlanta, GA) and saved as TIFF files.
Genome-wide gene expression analysis
RNA was extracted from tumor specimens and from
26262m m
3 tumor xenograft samples (derived from different
passages ranging from 1 to 3), which were taken from sacrificed
animals. Samples were snap-frozen and stored in liquid nitrogen
until use. Total RNA of homogenized tumor samples was
prepared with Trizol RNA extraction reagent (Invitrogen)
followed by purification using the RNeasy Mini Kit (Qiagen)
according to the manufacturer’s recommendations. A DNase I
(Qiagen) digestion step was included to eliminate genomic DNA.
The quality of the total RNA was checked for integrity using RNA
LabChips on the Agilent Bioanalyzer 2100 (Agilent Technologies)
and the concentration was measured on the Peqlab NanoDrop.
Only RNA with a RNA integrity number larger than 6.5 was used
for cDNA synthesis. The one-cycle eukaryotic target labeling assay
from Affymetrix was used according to manufacturer’s instructions
and as previously described [36]. Data analysis was performed as
previously described [36].
DNA extraction and mutation analysis
DNA was extracted from paraffin-embedded samples of colon
carcinoma with lymphatic and hepatic metastases. For every
tumor tissue, 10-mm sections were prepared, and an additional
representative 2-mm section was deparaffinised, stained with
haematoxylin and eosin, and analysed for detailed morphology.
Regions of tumor tissue were marked, and this tissue was
extracted with 0.2 M sodium hydroxide in 1 mM edetic acid and
neutralised with 100 mM TRIS-TE (pH 6.5). After extraction,
DNA was purified with Qiagen PCR purification kit (Qiagen,
Hilden, Germany). KRAS gene in exon 1 was analysed at codons
12 and 13 with pyrosequencing using a previously described assay
which has been shown to be of greater sensitivity [37]. BRAF gene
in exon 15 at codon 600 and PIK3CA gene in exon 9 at codons
539, 542, 545 and 546 and exon 20 at codons 1043, 1044, 1047
and 1049 were analysed with pyrosequencing as previously
described [14].
qRT-PCR
Total RNA was extracted from frozen tissues using TRIzol
reagent according to the protocol provided by the manufacturer
(Invitrogen, Carlsbad, CA). Total RNA was reverse-transcribed
into single-strand complementary DNA (cDNA) using moloney-
murine leukemia virus (M-MLV) reverse transcriptase (Promega,
Madison, WI). Briefly, the RNA was denatured by heating for
5 min at 70uC, followed by rapid cooling on ice, and then used
for reverse transcription (2 mg of total RNA, 25 U of RNase
inhibitor, 0.5 mmol/L of each dNTP, 1.5 mmol/L reverse primer
and 200 U of M-MLV reverse transcriptase in a total volume of
25 ml). For reverse transcription, tubes were incubated at 42uC
for 60 min. The expression of a randomly selected set of genes,
PDTT Xenograft Model for Novel Drugs Assessment
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excision repair-1 (ERCC-1), and thymidylate synthase (TS)i n
tissues in original tumors (G0) and tumors from the third
generation (G3) was analyzed using a fluorescence-based real-
time detection method (ABI PRISM 7700 Sequence Detection
System [TaqMan]; Perkin-Elmer Applied Biosystems) as previ-
ously described [38,39]. Specific primer pairs and probes are
listed in Table 1.T h eb-actin gene was used as an endogenous
control for normalization. The qRT-PCR reaction was carried
out in triplicate for each sample. The 25 ml PCR mixture was
consisted of 1 ml of cDNA template, 1 ml each of sense and anti-
sense primers, 0.75 mlo f5 9 FAM- and 39 TAMARA-labeled
oligonucleotide probe, 2 ml of dNTP mixture, 5 mlo f5 6reaction
buffer, and 0.125 ml of Taq DNA polymerase. Cycling conditions
were 50uC for 2 minutes, and 95uC for 10 minutes, followed by
46 cycles at 95uC for 15 seconds and 60uC for 1 minute.
Western blotting
Protein expression profiles were analyzed by western blotting as
previously described [31,40,41]. Briefly, lysates for immunoblot-
ting were prepared by adding lysis buffer [50 mM Tris-HCl
(pH 7.4), 1% Nonidet P-40, 0.5% sodium deoxycholate, 150 mM
NaCl, 0.02% sodium azide, and 0.1% SDS] containing protease
and phosphatase inhibitors (Sigma, St. Louis, MO) to the tumor
tissue homogenized in fluid nitrogen. After centrifugation at
15,000 rpm at 4uC for 10 min, the supernatants were collected,
and the protein concentration was determined using Bio-Rad
Protein Assay Kit (Bio-Rad, Hercules, CA). Protein extracts of
tumor lysates (30 mg) were added to a loading buffer [10 mmol/L
Tris-HCl (pH 6.8), 1% SDS, 25% glycerol, 0.1 mmol/L mercap-
toethanol, and 0.03% bromophenol blue], boiled, and separated
on 8% to 12% (w/v) polyacrylamide gels in the presence of SDS.
Molecular weights of the immunoreactive proteins were estimated
based on the relative migration with colored molecular weight
protein markers (Amersham Pharmacia Biotech, Piscataway, NJ).
After electrophoresis, the protein blots were electro-transferred to
PVDF membranes (Millipore, Billerica, MA). Then, the mem-
branes were blocked at room temperature with 5% nonfat milk in
TBS [10 mmol/L Tris-HCl (pH 7.5), 0.5 mol/L NaCl, and
0.05% (v/v) Tween 20] buffer for 1 h. The primary antibodies
were diluted at 1:1,000 and the membranes were incubated with
primary antibodies overnight at 4uC. The antibodies tested were
anti-Akt, anti-ERK, anti-MAPK, anti-mTOR antibodies, anti-
EGFR, anti-VEGF, anti-cleaved-caspase-3, anti-PCNA, and
phosphorylation-specific antibodies against Akt (Ser
308 and
Ser
473), ERK (Thr
202/Tyr
204), MAPK (Thr
180/Tyr
182) and
mTOR (Ser
2448). The next day, the membranes were washed
and incubated for 1 h at room temperature with rabbit
immunoglobulin G-horseradish peroxidase-conjugated secondary
antibodies (Santa Cruz Biotechnology), at a final dilution of
1:5,000. After washing thrice with TBS, antibody binding was
visualized using enhanced chemiluminescence detection system
(SuperSignal West Pico, Pierce) as described by the manufacturer
and autoradiography. To show equal protein loading, the blots
were stripped and reprobed for GAPDH.
Statistical analysis
Hierarchical clustering of all microarray experiments was done
based on all probe sets (54,675 probe sets) represented on the
Table 1. Sequences of primers and probes for qRT-PCR.
Primer and probe sequences
DPD
Forward primer 59- AGGACGCAAGGAGGGTTTG -39
Reverse primer 59- GTCCGCCGAGTCCTTACTGA -39
Probe 6FAM-59- CAGTGCCTACAGTCTCGAGTCTGCCAGTG -39-TAMRA
ERCC1
Forward primer 59-GGGAATTTGGCGACGTAATTC-39
Reverse primer 59-GCGGAGGCTGAGGAACAG-39
Probe 6FAM-59- CACAGGTGCTCTGGCCCAGCACATA -39-TAMRA
TS
Forward primer 59-GCCTCGGTGTGCCTTTCA-39
Reverse primer 59-GGCTCGATGTGATTCAGGTAAATAT-39
Probe 6FAM-59-CACGGGCCTGAAGCCAGGTGACTTTATA-39-TAMRA
b-actin
Forward primer 59-TGAGCGCGGCTACAGCTT-39
Reverse primer 59-TCCTTAATGTCACGCACGATTT-39
Probe 6FAM-59-ACCACCACGGCCGAGCGG-39-TAMRA
doi:10.1371/journal.pone.0028384.t001
Table 2. Tumor-bearing rate and tumor growth rate of the PDTT xenograft models.
Tumor-bearing rate
G1 (n=20) G2 (n=20) G3 (n=20)
Primary colon carcinoma 60% 80% 100%
Colon carcinoma lymphatic metastasis 60% 80% 100%
Colon carcinoma hepatic metastasis 80% 100% 100%
Tumor growth rate
a
G1 (n=10) G2 (n=10) G3 (n=10)
Primary colon carcinoma 141622.3 ds 93611.0 ds 3468.6 ds
Colon carcinoma lymphatic metastasis 111623.6 ds 67610.3 ds 3067.2 ds
Colon carcinoma hepatic metastasis 83613.2ds 4668.1 ds 2566.5 ds
Note:
ameasured when tumor volume arrived 1000 mm
3; G1, the first generation of xenograft; G2, the second generation of xenograft; G3, the third generation of xenograft;
ds, days.
doi:10.1371/journal.pone.0028384.t002
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positive correlation and complete linkage. Gene expression of
primary tumors was compared with the median arrays of replicate
tumors from each xenograft model in a paired t test. Drug
sensitivity data are presented as mean 6 SEM and analyzed by
SPSS 16.0 software. Difference among mean of the groups is
determined with one-way ANOVA. Comparison is considered to
be statistically significant if p,0.05.
Results
Patient-derived tumor tissues of colon carcinoma and its
corresponding lymphatic and hepatic metastases can be
implanted efficiently into nude mice
To test whether patient-derived tumor tissues of primary colon
carcinoma and its corresponding lymphatic and hepatic metastases
can be engrafted in nude mice, we implanted small pieces of
freshly tumor tissue into female athymic nude mice subcutane-
ously. After two to five months, tumors began to appear at the site
of implantation with 1000 to 1500 mm
3 in volume, and xenografts
were harvested for serial transplantation. The tumor-bearing rate
and tumor growth rate of different generations of PDTT
xenografts of primary colon carcinoma and its corresponding
lymphatic and hepatic metastases were illustrated in Table 2.
Histological and molecular characterization of xenografts
and comparison with original tumors
Using PDTT xenografts as models for preclinical anticancer
drug development is based on the assumption that the xenografts
would closely resemble the corresponding original tumors. For this
purpose, H&E staining, immunohistochemical staining, genome-
wide gene expression analysis, pyrosequencing, qRT-PCR and
western blotting were used to determine the biological stability of
the xenograft during serial transplantation compared with the
original tumor tissues. In this study, CK-20 and CDX-2 were used
as markers for determining the lymphatic and hepatic metastases
with a colon carcinoma primary. Immunohistochemical staining
showed a positive expression of CK-20 and CDX-2 in the
metastases (Fig. 1), which ascertained lymphatic and hepatic
metastases with an epithelial origin. Histological examination of
the H&E sections showed that the PDTT xenografts were
adenocarcinoma with features similar to the original surgical
specimens. Fig. 2 shows the morphology of the original tumors
(G0) of primary colon carcinoma with lymphatic and hepatic
metastases and their third generation (G3) implants in nude mice.
There were no significant morphological differences between the
tumor resected from the patient and the initial successful implants.
The explanted tumor pieces also showed similar VEGF and
EGFR expressions compared to the corresponding original tumors
(Fig. 3,4).
When using the PDTT xenograft models for testing of the
anticancer agents, especially molecularly targeted agents, detailed
characterization of the molecules is indispensable. For this
purpose, GeneChip HGU133Plus2.0 expression arrays (Affyme-
trix) was used to determine the status of the genome-wide gene
expression of the xenograft models, pyrosequencing was used to
determine the mutation status of some selected genes of the
Figure 1. Expression of CDX-2 and CK-20 in the tumor tissues
of lymphatic (A and B) and hepatic metastasis (C and D).
Original magnifications, 6200.
doi:10.1371/journal.pone.0028384.g001
Figure 2. Representative H&E stained tissues of primary colon carcinoma (A and B) and its corresponding lymphatic (C and D) and
hepatic (E and F) metastases and their early-generation of xenograft tumors. G0, the primary tumors; G3, the third generation of
xenografts. Original magnifications, 6100.
doi:10.1371/journal.pone.0028384.g002
PDTT Xenograft Model for Novel Drugs Assessment
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some randomized selected genes of the xenograft models, western
blotting was used to determine the expression of some randomized
selected signaling pathway proteins of the xenograft models during
serial transplantation compared with the original tumor tissues.
Our results showed that early passages of the PDTT xenograft
models of primary colon carcinoma with lymphatic and hepatic
metastases revealed a high degree of similarity with the original
clinical tumor samples with regard to KRAS, BRAF, EGFR, and
PIK3CA mutation status (see Fig. S1, S2, S3, S4) as well as
mRNA expression (data not shown). With regards to the western
blotting analysis of ‘randomized selected signaling proteins’, early
passages of the PDTT xenograft models of colon carcinoma
lymphatic and hepatic metastases revealed a high degree of
similarity with the original clinical tumor samples though these
phenomena did not exist between original clinical tumor sample of
primary colon cancer and its xenografts (Fig. 5). Based on the
results of genome-wide gene expression analysis, we calculated the
correlation coefficient between primary cancer and the xenograft
derived thereof. The correlation coefficient ranged between 0.988
and 0.991 (0.991 between primary colon carcinoma and its
xenograft, 0.989 between lymphatic metastasis and its xenograft,
and 0.988 between hepatic metastasis and its xenograft) indicating
a high degree of similarity between the primary cancer and the
corresponding xenograft model. A paired t test between the
primary tumors and xenografts revealed limited differentially
expressed probe sets. Clustering based on these probe sets showed
a limited distinction between primary tumors and xenografts
(Table S1, S2, S3, Fig. 6).
PDTT xenograft models of colon carcinoma and its
corresponding lymphatic and hepatic metastases for
assessment of a novel VEGF targeted agent
Our results indicated that during sequential passage, the PDTT
xenograft models retained their similarity to the corresponding
Figure 3. VEGF immunohistochemical staining of primary tumor tissues of primary colon carcinoma (A and B) and its
corresponding lymphatic (C and D) and hepatic (E and F) metastases and their early-generation xenograft tumor tissues. G0, the
primary tumors; G3, the third generation of xenografts. Original magnifications, 6100.
doi:10.1371/journal.pone.0028384.g003
Figure 4. EGFR immunohistochemical staining of primary tumor tissues of primary colon carcinoma (A and B) and its
corresponding lymphatic (C and D) and hepatic (E and F) metastases and their early-generation xenograft tumor tissues. G0, the
primary tumors; G3, the third generation of xenografts. Original magnifications, 6100.
doi:10.1371/journal.pone.0028384.g004
PDTT Xenograft Model for Novel Drugs Assessment
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signatures thus could be used for rapid screening of potential
therapeutics. To improve confidence of a novel VEGF blocker
during its early preclinical studies allowing for a faster decision is
one of purposes of using these xenograft models. To explore the
value of FP3 as an antitumor therapeutic and to compare it to
other effective agents targeting the VEGF pathway, we evaluated
its ability to block the growth of these xenograft models.
After implantation, tumors were allowed to grow for 10 days,
forming large retroperitoneal tumors .100 mm
3. Injections of
FP3 (15 mg/kg body weight), Avastin (10 mg/kg body weight) or
saline were then given i.v. twice per week for 21 days, after which
the animals were killed and tumors excised and measured. No
body weight-related toxicity was found in each group. FP3
significantly inhibited the growth of xenografts of primary colon
carcinoma and its lymphatic and hepatic metastases in nude mice
(Fig. 7), and resembled the well-defined and generally accepted
antitumor activity of Avastin [42].
To evaluate the effects of FP3 on tumor-associated angiogenesis,
selected tumors from the above studies were sectioned and
immunostained with antibodies to CD31 and a-SMA, so that the
vasculature could be visualized (Fig. 8, 9, 10). This analysis
revealed that vasculature was nearly absent in FP3-treated
xenografts. FP3 (treatment for 21 days) almost completely blocked
tumor-associated angiogenesis, with the stunted tumors being
largely avascular (Fig. 8: B, E, and H; Fig. 9: B, E, and H;
Fig. 10: B, E, and H). In contrast to the FP3-treated tumors,
control tumors in saline-treated mice not only were much larger
but also had a very high vascular density (Fig. 8: A, D, and G;
Fig. 9: A, D, and G; Fig. 10: A, D, and G). These results
indicate that FP3 administration reduces xenograft size and
concurrently causes decreased microvessel growth.
Figure 5. Exemplified immunoblotting data of the proteins Akt, pAkt (Ser
308 and Ser
473), ERK, pERK (Thr
202/Tyr
204), MAPK, pMAPK
(Thr
180/Tyr
182), mTOR, pmTOR (Ser
2448), EGFR, VEGF, Casepase-3, PCNA and GAPDH (as loading control) of primary colon
carcinoma and its corresponding lymphatic and hepatic metastases and their early-generation xenograft tumor tissues. G0, the
primary tumors; G3, the third generation of xenografts.
doi:10.1371/journal.pone.0028384.g005
Figure 6. Gene expression profiling of patient-derived tumor tissues and corresponding xenografts. A, hierarchical clustering based on
140 probe sets differentially expressed between primary colon carcinoma and its xenograft. B, hierarchical clustering based on 70 probe sets
differentially expressed between colon carcinoma lymphatic metastasis and its xenograft. C, hierarchical clustering based on 145 probe sets
differentially expressed between colon carcinoma hepatic metastasis and its xenograft. PCT, primary colon carcinoma. PCT Xe, primary colon
carcinoma xenograft. Lym, colon carcinoma lymphatic metastasis. Lym Xe, colon carcinoma lymphatic metastasis xenograft. Hep, colon carcinoma
hepatic metastasis. Hep Xe, colon carcinoma hepatic metastasis xenograft.
doi:10.1371/journal.pone.0028384.g006
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PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28384We next measured cell proliferation in the treated tumors. By
immunohistochemical staining, we found that VEGF expression
(Fig. 11) and PCNA expression (Fig. 12) in FP3- and Avastin-
treated tumors were significantly suppressed. However, EGFR
expression was not significantly different between any of the
treatment groups and saline-treated controls (Fig. 13), suggest-
ing that levels of EGFR are unlikely to be altered by the
treatments.
Because inhibition of VEGF signaling can decrease VEGFR-2
expression in certain types of blood vessels [43,44], we asked
whether VEGF/VEGFR blockade decreased receptor expression
in our tumor models. Treatment of the xenograft models with FP3
for 21 days, decreased expression of VEGFR-2, a marker for
growing vasculature (Fig. 14, 15). These results were consistent
with the disappearance of endothelial cells expressing this receptor
(Fig. 8, 9, 10).
Discussion
Rodent tumor models currently being used and which include
transgenic tumor models, and those generated by planting human
tumor cell lines subcutaneously in immunodeficient mice, do not
sufficiently represent clinical cancer characteristics, especially with
regard to metastasis and drug sensitivity [29]. The increasingly
used PDTT xenografts models implanted subcutaneously or in
subrenal capsule in immunodeficient mice provide a more
accurate reflection of human tumor biological characteristics than
tumor cell lines. The ability to passage patients’ fresh tumor tissues
Figure 7. Response curve of FP3 and Avastin in the PDTT xenograft models of primary colon carcinoma (A), lymphatic metastasis
(B), and hepatic metastasis (C). Ten mice per group were treated with the corresponding agent according to Materials and Methods. Data shown
are means 6 SEM. The differences between control tumor volumes, FP3-treated, and Avastin-treated tumor volumes were analyzed by using one-way
ANOVA.
*** p,0.001, versus control. Experiments were repeated at least two times with similar results.
doi:10.1371/journal.pone.0028384.g007
Figure 8. FP3 decreased vascular structure in the xenograft model of primary colon carcinoma. Vasculature was examined by
angiography with immunostaining for endothelial cells (using anti-CD31 antibody; bar=100 mm), and pericytes (using anti-a-SMA antibody;
bar=100 mm). There was a paucity of vessels identified in FP3-treated tumors.
doi:10.1371/journal.pone.0028384.g008
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PLoS ONE | www.plosone.org 8 December 2011 | Volume 6 | Issue 12 | e28384into large numbers of immunodeficient mice provides possibilities
for better preclinical testing of new therapies for the treatment and
better outcome for cancer.
In our study, we successfully established the PDTT xenograft
models of primary colon carcinoma and its corresponding
lymphatic and hepatic metastases. One of vital questions relating
Figure 9. FP3 decreased vascular structure in the xenograft model of colon carcinoma lymphatic metastasis. Vasculature was
examined by angiography with immunostaining for endothelial cells (using anti-CD31 antibody; bar=100 mm), and pericytes (using anti-a-SMA
antibody; bar=100 mm). There was a paucity of vessels identified in FP3-treated tumors.
doi:10.1371/journal.pone.0028384.g009
Figure 10. FP3 decreased vascular structure in the xenograft model of colon carcinoma hepatic metastasis. Vasculature was examined
by angiography with immunostaining for endothelial cells (using anti-CD31 antibody; bar=100 mm), and pericytes (using anti-a-SMA antibody;
bar=100 mm). There was a paucity of vessels identified in FP3-treated tumors.
doi:10.1371/journal.pone.0028384.g010
PDTT Xenograft Model for Novel Drugs Assessment
PLoS ONE | www.plosone.org 9 December 2011 | Volume 6 | Issue 12 | e28384to PDTT xenografts is whether tumor passage in the experimental
mice alters the phenotype of primary cancer cells. When
developing the anticancer agents, especially molecularly targeted
agents, detailed characterisation of the molecules is indispensable.
If there are fundamental changes in tumors from before to after
their engrafting, the model may not do well in reflecting the
features of human cancers. Therefore, the practicability of this
model as a screening platform for new drug development for this
Figure 11. Effects of FP3 and Avastin on the expression of VEGF in the PDTT xenograft models of primary colon carcinoma (A–C),
lymphatic metastasis (D–F), and hepatic metastasis (G–I). Original magnifications, 6100.
doi:10.1371/journal.pone.0028384.g011
Figure 12. Effects of FP3 and Avastin on the expression of PCNA in the PDTT xenograft models of primary colon carcinoma (A–C),
lymphatic metastasis (D–F), and hepatic metastasis (G–I). Original magnifications, 6100.
doi:10.1371/journal.pone.0028384.g012
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PLoS ONE | www.plosone.org 10 December 2011 | Volume 6 | Issue 12 | e28384disease will be limited. Similarly, the value of this model as a tool
to individualise patient treatment would be limited [40]. Using
PDTT xenografts as models for preclinical anticancer drug
development is based on the assumption that the xenografts
would closely resemble the corresponding original tumors. In our
study, we firstly demonstrated that early passages of the PDTT
xenograft models of primary colon carcinoma, lymphatic and
hepatic metastases revealed a high degree of similarity with the
Figure 13. Effects of FP3 and Avastin on the expression of EGFR in the PDTT xenograft models of primary colon carcinoma (A–C),
lymphatic metastasis (D–F), and hepatic metastasis (G–I). Original magnifications, 6100.
doi:10.1371/journal.pone.0028384.g013
Figure 14. Effects of FP3 and Avastin on the expression of VEGFR-2 in the PDTT xenograft models of primary colon carcinoma (A–
C), lymphatic metastasis (D–F), and hepatic metastasis (G–I). Original magnifications, 6100.
doi:10.1371/journal.pone.0028384.g014
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PLoS ONE | www.plosone.org 11 December 2011 | Volume 6 | Issue 12 | e28384original clinical tumor sample with regard to histology (Fig. 2),
immunohistochemistry (Fig. 3, 4), mutation status (see Fig. S1,
S2, S3, S4), mRNA expression (data not shown) as well as genes
expression (Fig. 6). As these xenografts models retain similar
histopathological features and molecular signatures as the original
tumors, they could be used for rapid screening of potential
therapeutics not only on the primary tumor, but also on its
corresponding metastases.
One of the general applications of the PDTT xenograft models
of primary colon carcinoma and its corresponding lymphatic and
hepatic metastases is that they can be used as an in vivo screening
tool to test the response of both the primary tumor and the
metastases to some certain novel drugs. Furthermore, these models
may help us to clear whether the primary tumors and
corresponding metastases have different response to the same
anticancer drugs. In this study, the PDTT xenograft models of
primary colon carcinoma and its corresponding lymphatic and
hepatic metastases were used for assessment of a novel VEGF
targeted agent, FP3. As shown in results, FP3 significantly
inhibited the growth of xenografts of primary colon carcinoma
and its corresponding lymphatic and hepatic metastases and
concurrently caused inhibition of tumor vessels growth dramati-
cally [Fig. 7, 8, 9, 10]. These results coincide with our previous
works [24,28].
In conclusion, our work successfully established the PDTT
xenograft models of colon carcinoma with lymphatic and hepatic
metastasis useful for testing of a novel molecularly anti-VEGF
targeted agent, FP3. Early passages of the PDTT xenograft models
of primary colon carcinoma, lymphatic and hepatic metastases
revealed a high degree of similarity with the original clinical tumor
samples. They provide appropriate models for testing of novel
molecularly targeted agents. These models may also help us to
clear whether the primary tumors and corresponding metastases
have different response to the same anticancer drugs.
Supporting Information
Figure S1 Mutation analysis by pyrosequencing. Se-
quence data of KRAS gene in exon 1 at codons 12 and 13 of
primary tumor tissues and their early-generation xenograft models
tumor tissues. A, standard wild-type sample. Tumor tissues from
surgical specimens of primary colon carcinoma (B) and its
corresponding lymphatic metastasis (D) and hepatic metastasis
(F). Tumor tissues from the third generation of xenograft models of
primary colon carcinoma (C) and its corresponding lymphatic
metastasis (E) and hepatic metastasis (G).
(TIF)
Figure S2 Mutation analysis by pyrosequencing. Se-
quence data of BRAF gene in exon 15 at codon 600 of primary
tumor tissues and their early-generation xenograft models tumor
tissues. A, standard wild-type sample. Tumor tissues from surgical
specimens of primary colon carcinoma (B) and its corresponding
lymphatic metastasis (D) and hepatic metastasis (F). Tumor tissues
from the third generation of xenograft models of primary colon
carcinoma (C) and its corresponding lymphatic metastasis (E) and
hepatic metastasis (G).
(TIF)
Figure S3 Mutation analysis by pyrosequencing. Se-
quence data of PIK3CA gene in exon 9 at codons 539, 542, 545
and 546 of primary tumor tissues and their early-generation
xenograft models tumor tissues. A, standard wild-type sample.
Tumor tissues from surgical specimens of primary colon
carcinoma (B) and its corresponding lymphatic metastasis (D)
and hepatic metastasis (F). Tumor tissues from the third generation
of xenograft models of primary colon carcinoma (C) and its
corresponding lymphatic metastasis (E) and hepatic metastasis (G).
(TIF)
Figure S4 Mutation analysis by pyrosequencing. Se-
quence data of PIK3CA gene in exon 20 at codons 1043, 1044,
1047 and 1049 of primary tumor tissues and their early-generation
xenograft models tumor tissues. A, standard wild-type sample.
Tumor tissues from surgical specimens of primary colon
carcinoma (B) and its corresponding lymphatic metastasis (D)
and hepatic metastasis (F). Tumor tissues from the third generation
of xenograft models of primary colon carcinoma (C) and its
corresponding lymphatic metastasis (E) and hepatic metastasis (G).
(TIF)
Table S1 Genes differentially expressed in patient
primary colon cancer specimens and its xenograft.
(DOC)
Table S2 Genes differentially expressed in patient colon
cancer lymphatic metastasis specimens and its xeno-
graft.
(DOC)
Table S3 Genes differentially expressed in patient
colon cancer hepatic metastasis specimens and its
xenograft.
(DOC)
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